证券代码：002004 证券简称：华邦健康 公告编号：2023026 华邦生命健康股份有限公司 关于实际控制人及其一致行动人部分股份质押展期 及质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于近日接到公司实际控制 人张松山先生及其一致行动人张一卓先生的通知，获悉其将所持有本公司的部分 股份办理质押展期及质押手续,具体情况如下： 二、本次质押基本情况 | 股东 | 是否为控股股东 或第一大股东及 | 本次质押数 | 占其所持股 | 占公司总 | 是否 为限 | 是否为 补充质 | 质押起始 | 质押到期日 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 量（股） | 份比例 | 股本比例 | | | 日 | | | 用途 | | | 其一致行动人 | | | | 售股 | 押 | | | | | | 张松山 | 是 | 2,770,000 | 2.37% | 0.14% | ...

华邦生命健康股份有限公司 2023 年第三季度报告 华邦生命健康股份有限公司 2023年第三季度报告 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3.第三季度报告是否经过审计 证券代码：002004 证券简称：华邦健康 公告编号：2023025 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 □是 否 1 华邦生命健康股份有限公司 2023 年第三季度报告 会计政策变更的原因及会计差错更正的情况 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 会计政策变更 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------- ...

华邦生命健康股份有限公司 2023 年半年度报告全文 第一节 重要提示、目录和释义 华邦生命健康股份有限公司 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完整，不 存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 2023 年半年度报告 【2023 年 8 月】 1 华邦生命健康股份有限公司 2023 年半年度报告全文 2 | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介和主要财务指标 6 | | 第三节 管理层讨论与分析 9 | | 第四节 公司治理 25 | | 第五节 环境和社会责任 27 | | 第六节 重要事项 43 | | 第七节 股份变动及股东情况 53 | | 第八节 优先股相关情况 57 | | 第九节 债券相关情况 58 | | 第十节 财务报告 59 | 华邦生命健康股份有限公司 2023 年半年度报告全文 公司负责人张松山、主管会计工作负责人王剑及会计机构负责人(会计主管人员)王剑声明：保证 本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告中涉及的未来 ...

iuapon 华邦健康 2022 股票简称:华邦健康 股票代码:002004 年度报告 修护 祛痘 修护 祛痘 生产基地会面投产 更加智能化、绿色化、 2022 年、公司长寿原料药生产基地和汉江国际原料药生产基地完工投产。公司已 形成以水土生产基地、温江生产基地、沈阳生产基地、内蒙古通辽生产基地为主的四 大制剂生产基地和以长寿原料药基地、合川原料药基地、汉中国际原料药基地为主的 三大原料药生产基地。整体产能更上一台阶,满足公司中长期发展战略,同时,公司 将继续积极探索和实施 CDMO/CMO 业务。 华 邦 生 命 健 康 股 份 有 限 公 司 HUAPONT LIFE SCIENCES CO.,LTD 2022年,面对全球经济增长的较大不确定性,公司管理层笃行不 怠,积极应对,始终坚定执行医药、医疗"大健康"发展战略、实现各 项业务稳健发展。 过去一年、公司积极推进医药产品研发,1个制剂产品获批、7个 原料药品种获得海外认证;继续布局"大皮肤"产业链,推出 10 余款功 能性护肤品。公司汉江国际原料药生产基地和华邦胜凯原料药生产基 地正式投产,医药生产基地全面升级,更加智能化、绿色化。北京华 生康复医院正 ...

Financial Performance - The company's operating revenue for the current period is CNY 2,975,546,798.68, a decrease of 12.46% compared to the same period last year[9]. - Net profit attributable to shareholders of the listed company is CNY 177,137,767.78, an increase of 5.05% year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY 168,985,255.18, reflecting a 4.78% increase compared to the previous year[9]. - The net profit for the first quarter was 294,842,240.23 CNY, a decrease from 319,793,662.55 CNY in the previous year, representing a decline of approximately 7.3%[44]. - The total profit amounted to 366,979,165.37 CNY, down from 478,322,104.63 CNY, indicating a decrease of about 23.2% year-over-year[44]. - The company's operating profit was 373,052,903.14 CNY, compared to 479,840,467.75 CNY in the same period last year, reflecting a decline of approximately 22.2%[44]. - The basic earnings per share increased to 0.0895 CNY from 0.0852 CNY, showing a growth of about 2.7%[44]. Cash Flow - The net cash flow from operating activities shows a significant decline of 108.00%, with a current value of CNY -12,813,669.92[9]. - Net cash flow from operating activities turned negative at -¥12,813,669.92 compared to ¥160,139,339.82, a decline of 108.00% attributed to decreased sales volume[34]. - Cash inflow from investment activities totaled ¥2,619,725,609.42, an increase from ¥2,055,850,849.49 in the previous period[25]. - Cash outflow for investment activities was ¥2,667,219,986.51, significantly higher than ¥2,029,269,337.09 in the previous period[25]. - The company reported a net cash flow from financing activities of ¥271,341,170.39, compared to ¥41,768,134.81 in the previous period[25]. - The net cash outflow from financing activities was -7,096,160.62 CNY, an improvement compared to -143,352,411.67 CNY in the previous year[46]. - The total cash outflow from financing activities was 1,695,183,231.01 CNY, compared to 2,341,225,774.83 CNY in the previous year, reflecting a decrease of approximately 27.6%[46]. - The company reported a foreign exchange impact of -11,413,514.64 CNY on cash and cash equivalents, contrasting with a positive impact of 5,674,000.87 CNY in the previous year[46]. Assets and Liabilities - Total assets at the end of the reporting period amount to CNY 30,225,558,790.97, representing a 0.67% increase from the end of the previous year[9]. - Total liabilities amounted to ¥13,380,018,004.07, slightly down from ¥13,473,613,165.12 in the previous period[22]. - Shareholders' equity attributable to the listed company is CNY 10,368,342,116.43, up by 1.73% compared to the previous year[9]. - Total equity attributable to shareholders reached ¥10,368,342,116.43, up from ¥10,191,961,981.05 in the previous period[22]. - Deferred income increased to ¥305,678,087.18 from ¥278,214,493.71, indicating a growth of about 9.9%[22]. Investments and Subsidiaries - The company established a new subsidiary, Chongqing Songshan Membership Hospital Co., Ltd., with a registered capital of CNY 5 million, aiming to integrate medical resources[18]. - The company reported a decrease in trading financial assets by 32.53%, primarily due to the redemption of financial products during the reporting period[14]. - Investment income decreased significantly to ¥10,000,471.18 from ¥95,932,564.71, a decline of 89.58% due to reduced investment income from associated enterprises[34]. - Accounts receivable financing decreased by 30.14%, mainly due to a reduction in notes receivable[14]. - Contract liabilities decreased by 52.24%, attributed to the delivery of goods during the reporting period[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 89,791, with the largest shareholder, Tibet Huibang Technology Co., Ltd., holding 18.71%[34]. - The top ten shareholders include Tibet Huibang Technology Co., Ltd. (18.71%), Zhang Songshan (5.91%), and Dong Xiaoming (3.58%) among others[34]. Research and Development - Research and development expenses increased to ¥101,564,101.36 from ¥83,364,496.79, marking a growth of approximately 21.8%[22].